Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
September 08, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing...
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
September 03, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
Patent challenge initiated by Bausch Health Companies NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused...
Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
August 06, 2020 07:08 ET
|
Sol-Gel Technologies Ltd.
New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020Top-line generic product revenue of $1.1 million in 2Q 2020Launch of additional generic product expected...
Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
July 29, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021
July 28, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates
June 29, 2020 07:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
June 16, 2020 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel to Present at Upcoming Healthcare Investor Conferences
May 27, 2020 09:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update
May 14, 2020 07:05 ET
|
Sol-Gel Technologies Ltd.
New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectivelyCompleted a $23 million underwritten public offering in February with an...
Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
May 07, 2020 16:05 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...